H1N1 influenza:
Responding to a pandemic

As H1N1 flu continues to make headlines across the world, GlaxoSmithKline is responding to the flu pandemic.


GSK is investing in the development of vaccines for the influenza A (H1N1) strain of flu and the increased production of the anti-viral Relenza through its own manufacturing facilities and through partnerships with other companies.


More about influenza A (H1N1)

 

Announcements

Image of virus

Image of blog tab title
To help millions of people live longer, healthier lives-that's why we work at GSK.

   

   

Recent headlines

GSK News ServicesGSK News Services

image of gray arrow US News alert service
image of gray arrow RSS News feed

What are RSS feeds?

Leading the way to make clinical trial data more transparent

Learn about flu treatment

Find health information

Save money on your prescriptions

Join GSK